Healthcare diagnostics company Labcorp Holdings (NYSE: LH) announced better-than-expected revenue in Q3 2026, with sales up 6.9% year on year to $3.81 billion. The company’s full-year revenue guidance of $14.83 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $4.78 per share was 2.9% above analysts’ consensus estimates.
Is now the time to buy LH? Find out in our full research report (it’s free for active Edge members).
Labcorp (LH) Q3 2026 highlights:
- Revenue $3.81 billion vs S&P analysts’ estimates of $3.76 billion (6.9% year-on-year growth, 1.2% beat)
- Adjusted EPS $4.78 vs S&P analysts’ estimates of $4.64 (2.9% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $14.83 billion at the midpoint from $14.77 billion
- Adjusted EPS guidance Management slightly raised its full-year adjusted EPS guidance to $18.50 at the midpoint
- Operating margin 10.6%, in line with the same quarter last year
- Organic revenue rose 5.5% year on year (beat)
- Market capitalization $29.25 billion
StockStory’s take
Labcorp’s third quarter results were marked by strong growth in specialty testing and continued expansion in biopharma laboratory services, leading to performance that exceeded Wall Street’s expectations. Management highlighted disciplined execution and volume growth across diagnostics as key contributors. CEO Adam Schechter attributed the quarter's momentum to “continued strength in central laboratories and specialty testing,” underscoring the value of Labcorp’s clinical partnerships and recent advancements in areas such as oncology and neurology.
Looking forward, Labcorp’s updated guidance reflects confidence in its ability to offset anticipated reimbursement headwinds, particularly those related to the pending PAMA (Protecting Access to Medicare Act) changes. Management emphasized the role of recent acquisitions, ongoing productivity initiatives, and demand for high-growth specialty areas in sustaining growth. CFO Julia Wang stated, “We remain very positive about the prospects of 2027 and expect to offset a portion of the PAMA impact through strong business momentum, business development opportunities, and continued Launchpad savings.”
Key insights from management’s remarks
Management credited the quarter’s performance to robust demand in specialty testing, operational efficiencies, and the recent expansion of both its diagnostics and biopharma services footprint.
- Specialty testing drove growth: Labcorp’s specialty testing business, including oncology, neurology, and women’s health, grew about three times faster than the broader diagnostics market, driven by emerging therapies and higher physician adoption rates.
- New product and test launches: The company launched an FDA-cleared pTau217 test for Alzheimer’s disease and a hepatitis D reflex test, along with collaborations to advance precision medicine, such as a study with the Knight Cancer Institute for MRD (minimal residual disease) testing in bladder cancer.
- Strategic acquisitions expand reach: Labcorp acquired MLM Medical Labs, establishing a wholly owned central laboratory network across four continents, and announced agreements to acquire assets from BioReference, Myriad Genetics’ prenatal health testing, and Millennium Health, each targeting accretive contributions to earnings.
- Operational efficiencies through technology: Launchpad productivity initiatives, increased laboratory automation, and digital pathology solutions contributed to margin expansion and sustained cost control, with automation facilitating improved customer experience and productivity.
- Biopharma laboratory services momentum: The biopharma segment saw strong organic growth, particularly in central lab services, supported by robust demand from large pharmaceutical clients and a healthy book-to-bill ratio, indicating solid future revenue visibility.
Drivers of future performance
Management’s outlook for the remainder of the year centers on leveraging specialty testing, recent acquisitions, and cost discipline to offset reimbursement risks.
- Reimbursement headwinds: The company anticipates a significant impact from upcoming PAMA-related Medicare reimbursement cuts in 2027. Management is preparing to counter these headwinds with a combination of volume growth, cost efficiencies from Launchpad initiatives, and contributions from recent acquisitions.
- Acquisition integration and synergy: Labcorp expects recently announced deals, including those with BioReference, Myriad Genetics, and Millennium Health, to be accretive to earnings in their first year and to drive margin improvement as integration progresses and operational synergies are realized.
- Expansion of specialty and biopharma services: Growth in high-value specialty testing and biopharma laboratory services is forecast to continue, supported by demand for advanced diagnostics in oncology, neurology, and cardiometabolic disorders, as well as ongoing investments in technology and global infrastructure.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will closely watch (1) the pace and effectiveness of integrating newly acquired businesses, (2) Labcorp’s ability to sustain specialty testing growth and biopharma service momentum, and (3) early signs of how the company manages PAMA-related reimbursement headwinds. Progress on operational efficiency initiatives and the launch of new diagnostics will also be key metrics for ongoing evaluation.
Labcorp currently trades at $366.28, up from $331.17 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
